Jazz Pharmaceuticals (NASDAQ:JAZZ) Receives "Buy" Rating from Needham & Company LLC

Key Points

• Jazz Pharmaceuticals received a "buy" rating from Needham & Company LLC, with a target price of $202.00, indicating a potential upside of 69.46% from its current stock price.
• The company reported a loss of ($8.25) EPS for the recent quarter, which fell short of the estimated ($5.61) EPS, while revenue matched expectations at $1.05 billion.
• Insider ownership is relatively low, with 4.30% of the company's stock held by insiders, as recent sales by CEO Bruce C. Cozadd indicate a decrease in his holdings.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at Needham & Company LLC in a report issued on Wednesday,Benzinga reports. They currently have a $202.00 target price on the specialty pharmaceutical company's stock. Needham & Company LLC's price target would indicate a potential upside of 69.46% from the company's current price.

Several other brokerages also recently commented on JAZZ. Royal Bank Of Canada dropped their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price objective on the stock. Robert W. Baird dropped their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Finally, Morgan Stanley dropped their price objective on Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating on the stock in a report on Wednesday, August 6th. Thirteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $181.43.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $119.20 on Wednesday. The company has a market cap of $7.23 billion, a P/E ratio of -17.71, a PEG ratio of 7.42 and a beta of 0.34. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals has a one year low of $95.49 and a one year high of $148.06. The business's 50-day simple moving average is $112.07 and its 200 day simple moving average is $117.13.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts forecast that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the transaction, the chief executive officer owned 436,973 shares in the company, valued at approximately $47,031,403.99. This trade represents a 0.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Hurley Capital LLC acquired a new position in Jazz Pharmaceuticals during the 1st quarter valued at approximately $25,000. Elequin Capital LP boosted its position in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after purchasing an additional 183 shares during the period. Parallel Advisors LLC boosted its position in Jazz Pharmaceuticals by 85.6% during the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after purchasing an additional 119 shares during the period. Picton Mahoney Asset Management boosted its position in Jazz Pharmaceuticals by 2,445.5% during the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after purchasing an additional 269 shares during the period. Finally, Spire Wealth Management boosted its position in Jazz Pharmaceuticals by 137.6% during the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after purchasing an additional 161 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.